Fate Therapeutics Announces Generation of CAR-targeted, TCR-null CD8αβ+ T Cells from Clonal Engineered Master … – GlobeNewswire (press release)
|
Fate Therapeutics Announces Generation of CAR-targeted, TCR-null CD8αβ+ T Cells from Clonal Engineered Master …
GlobeNewswire (press release) SAN DIEGO, Dec. 09, 2017 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today the generation of … First Quadrant LP Raised First Financial Indiana (THFF) Stake By $534954; Profile of 8 Analysts Covering Fate … |
